Drug
Ly5830966
Ly5830966: highest development phase Phase 1, developed by Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY5830966 NCT06343805 | Phase 1 | Primary Myelofibrosis |
Latest
No recent events.
Follow Ly5830966 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.